Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigational, oral, highly selective inhibitor of the HER2 tyrosine kinase. METHODS: We randomly assigned patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine, who had or did not have brain metastases, to receive either tucatinib or placebo, in combination with trastuzumab and capecitabine. The primary end point was progression-free survival among the first 480 patients who underwent randomization. Secondary end points, assessed in the total population (612 patients), included overall survival, progression-free survival among patients with brain metastases, confirmed objective response rate, and safety. RESULTS: Progression-free survival at 1 year was 33.1% in the tucatinib-combination group and 12.3% in the placebo-combination group (hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.42 to 0.71; P<0.001), and the median duration of progression-free survival was 7.8 months and 5.6 months, respectively. Overall survival at 2 years was 44.9% in the tucatinib-combination group and 26.6% in the placebo-combination group (hazard ratio for death, 0.66; 95% CI, 0.50 to 0.88; P = 0.005), and the median overall survival was 21.9 months and 17.4 months, respectively. Among the patients with brain metastases, progression-free survival at 1 year was 24.9% in the tucatinib-combination group and 0% in the placebo-combination group (hazard ratio, 0.48; 95% CI, 0.34 to 0.69; P<0.001), and the median progression-free survival was 7.6 months and 5.4 months, respectively. Common adverse events in the tucatinib group included diarrhea, palmar-plantar erythrodysesthesia syndrome, nausea, fatigue, and vomiting. Diarrhea and elevated aminotransferase levels of grade 3 or higher were more common in the tucatinib-combination group than in the placebo-combination group. CONCLUSIONS: In heavily pretreated patients with HER2-positive metastatic breast cancer, including those with brain metastases, adding tucatinib to trastuzumab and capecitabine resulted in better progression-free survival and overall survival outcomes than adding placebo; the risks of diarrhea and elevated aminotransferase levels were higher with tucatinib. (Funded by Seattle Genetics; HER2CLIMB ClinicalTrials.gov number, NCT02614794.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This was achieved at the expense of increased toxicity, mostly diarrhoea and elevated aminotransferase levels of grade ≥3, but did not lead to frequent treatment discontinuation.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
In the citing paper
“Tucatinib, a highly selective inhibitor of the HER2 tyrosine kinase, used in combination with capecitabine and trastuzumab in a population of ABC patients pretreated with trastuzumab, pertuzumab and trastuzumab emtansine (T-DM1), demonstrated improvement of PFS (median 7.8 months versus 5.6 months, HR 0.54; 95% CI 0.42-0.71, P < 0.001) and OS (median 21.9 months versus 17.4 months, HR 0.66; 95% CI”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [62]
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
The National Comprehensive Cancer Network (NCCN).
Wood, E. H. (2004) · Journal of the Medical Library Association JMLA · Cited by 2,845
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Baselga, J., Cortés, J., Kim, S.-B., Im, S.-A., Hegg, R., Im, Y.-H., Roman, L., Pedrini, J. L., Pienkowski, T., Knott, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113216 · Cited by 2,532
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Cardoso, F., Costa, A., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Bhattacharyya, G., Biganzoli, L., Cardoso, M. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw544 · Cited by 2,033
Self-citationBendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citation4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., Harbeck, N., Aguilar Lopez, B., Barrios, C. H., Bergh, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy192 · Cited by 1,171
Self-citationSwain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationOwens, M. A., Horten, B. C., & Da Silva, M. M. (2004) · Clinical Breast Cancer · doi:10.3816/cbc.2004.n.011 · Cited by 657
Research works printed but not linked: 1
- Pheneger T, Bouhana K, Anderson D, et al. In vitro and in vivo activity of ARRY-380: a potent, small molecule inhibitor of ErbB2. Cancer Res 2009;69:1795-1795. abstract.
Cited by
Items 901–1,000 of 1,000
HER2-low — the new subtype of breast cancer?
Pogoda, K., Jagiełło-Gruszfeld, A., & Nowecki, Z. I. (2022) · Oncology in Clinical Practice · doi:10.5603/ocp.2022.0001 · Cited by 2
Zhao, M., Liu, J., Tang, Y., Zhang, L., Ge, X., Chen, M., Wen, Q., Zhu, L., & Ma, Q. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213115 · Cited by 2
Miao, Y., Chen, J., Deng, R., & Liu, Y. (2022) · Journal of Oncology · doi:10.1155/2022/9449489 · Cited by 3
“It prevents cancer cell mitosis and affects protein synthesis, and is often used in the treatment of metastatic breast cancer, especially for metastatic breast cancer that progresses after taxol or anthracycline chemotherapy [9].”
BackgroundCollet, L., Eberst, L., Gauthier, L., Debled, M., Hrab, L., Mouret‐Reynier, M., Desmoulins, I., Gonçalvès, A., Campone, M., Ferrero, J.-M., et al. (2023) · Breast Cancer · doi:10.1007/s12282-022-01427-0 · Cited by 2
“02), a HR that is similar to the one observed for the primary endpoint on the whole population [28, 31].”
BackgroundSelf-citationAntonazzo, I. C., Cortesi, P. A., Sopo, G. M., Mazzaglia, G., Conte, P., & Mantovani, L. G. (2023) · Cancers · doi:10.3390/cancers15041175 · Cited by 2
“8 m2 [11], in line with Italian BC population data [18].”
BackgroundMethodResultInfluentialHouten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., Boland, A., Dundar, Y., Marsden, A., Malik, Z., et al. (2023) · PharmacoEconomics - Open · doi:10.1007/s41669-023-00405-2 · Cited by 2
Long, S., Xu, J., & Huang, H. W. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02461-1 · Cited by 2
Review: A Roadmap to Use Nonstructured Data to Discover Multitarget Cancer Therapies
Scoarta, S., Küçükosmanoğlu, A., Bindt, F., Pouwer, M. G., & Westerman, B. A. (2023) · JCO Clinical Cancer Informatics · doi:10.1200/cci.22.00096 · Cited by 3
Biskup, E. M., Montavon, C., Müller, A., Leo, C., Nussbaum, C. U., Margarint, E. L. G., Koychev, D., Schreiber, A., Taverna, C., Thorn, D. R., et al. (2023) · Molecular and Clinical Oncology · doi:10.3892/mco.2023.2648 · Cited by 2
“Vinorelbine 6 (17) 3 (21) 1 (17) 2 (13)”
Galve-Calvo, E., Alonso‐Babarro, A., Martinez‐García, M., Pi‐Figueras, M., Villalba, G., Alonso, S., & Contreras, J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02538-6 · Cited by 3
Relationship Between Motivation and Performance of Posyandu Cadres
Wijayanti, N., Vanchapo, A. R., & Darmayanti, A. T. (2023) · Journal of World Future Medicine Health and Nursing · doi:10.55849/health.v1i1.434 · Cited by 2
Mehta, S., Xie, J., Ionescu‐Ittu, R., Nie, X., & Kwong, W. J. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00241-8 · Cited by 2
“In the HER2CLIMB trial, tucatinib demonstrated superior outcomes versus placebo, with a median PFS of 7.8 months and a median OS of 21.9 months [38].”
BackgroundInfluentialBartol, A., Dreßler, K., Isbary, G., Lechner, C., Niemann, I., & Petschulies, M. (2023) · Forum · doi:10.1007/s12312-023-01253-1 · Cited by 2
Dai, L., Huang, Q.-Y., Guo, R., Zhu, K., Tang, Y., Chen, D., & Huang, S. (2023) · Clinical Medicine Insights Oncology · doi:10.1177/11795549231202463 · Cited by 2
Jackson, E. B., Curry, L. C., Mariano, C. J., Hsu, T., Cook, S., Pezo, R. C., Savard, M.-F., Desautels, D. N., Leblanc, D., & Gelmon, K. A. (2023) · Current Oncology · doi:10.3390/curroncol31010010 · Cited by 2
Self-citationShao, X., Yang, D., Shan, L., Yan, X., Xu, D., Li, L., Sun, Y., Yu, Q., Zhou, H., Ding, Y.-B., et al. (2024) · Archives of Toxicology · doi:10.1007/s00204-023-03670-6 · Cited by 2
“A Phase II clinical trial (NCT02614794) demonstrated the superiority of the Tucatinib plus Tras-tuzumab and Capecitabine in extending progression-free survival (PFS) and OS in metastatic HER2 + breast cancer patients (Murthy et al. 2018, 2020).”
Neurotoxicity-sparing radiotherapy for brain metastases in breast cancer: a narrative review
Buczek, D., Zaucha, R., & Jassem, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2023.1215426 · Cited by 3
“This development may potentially defer the need for immediate radiotherapy in BCBMs (111, 125).”
BackgroundInfluentialÁvila, J., Leone, J., Vallejo, C. T., & Leone, J. P. (2024) · Medical Sciences · doi:10.3390/medsci12010015 · Cited by 2
“In addition, we cannot assess the impact of the implementation of new drugs like trastuzumab deruxtecan, tucatinib, or sacituzumab govitecan [49–51], which have been shown to have a positive impact on survival in the general population, as these agents were approved after 2019.”
BackgroundFadrus, P., Vybíhal, V., Rošková, I., Selingerová, I., Smrčka, M., Jančálek, R., Šáňa, J., Slabý, O., Pospíšil, P., Hynková, L., et al. (2024) · Reports of Practical Oncology & Radiotherapy · doi:10.5603/rpor.99362 · Cited by 2
“…melanoma) [4], ipilimumab and nivolumab (melanoma) [5], tucatinib and trastuzumab (HER2-positive intracranial metastatic breast cancer) [6], or other types of targeted therapy are usually referred to some kind of local treatment later during the natural course of the intracranial…”
BackgroundRodriguez, G. F., Shah, A. S., & Maderal, A. D. (2024) · Breast Disease · doi:10.3233/bd-230053 · Cited by 2
Lam, C. J. K., Diessner, B. J., Andrade, K., Stackland, S., Park, L., Mehta, S., Lin, F., & Kwong, J. (2024) · Journal of Comparative Effectiveness Research · doi:10.57264/cer-2023-0166 · Cited by 2
“For previously treated patients with HER2 + mBC, including brain metastases, adding tucatinib to trastuzumab and capecitabine was shown to improve OS [12] .”
BackgroundCerebral Metastases in Breast Cancer Patients: a Narrative Review
Müller, C., Schmidt, G., Solomayer, E., Popp, I., Grosu, A., Juhasz‐Böss, I., Jung, L., & Huwer, S. I. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00558-x · Cited by 2
“The combination showed an improved intracranial objective response rate, as well as improved progression free survival (5.7 months) and a longer median overall survival of 9.1 months [65, 66 •• ].”
InfluentialCiapponi, A., Bardach, A., Colaci, C., Cairoli, F. R., Argento, F., Korbenfeld, E. P., & Martí, S. G. (2024) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2024.411.13351 · Cited by 4
Fortuna, A., Luz, P., Cordeiro, M., Gosálbez, B., Campôa, E., Claudino, M., Alves, P., Costa, J. G., Fernandes, A. S., & Pinto, C. M. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33886 · Cited by 2
“In addition, new treatment options with demonstrated brain activity, such as tucatinib, trastuzumab deruxtecan, and pyrotinib, are now available and may be used even in the presence of active lesions [18 – 20].”
BackgroundAdvances from targeted therapy for non‐metastatic HER2‐positive inflammatory breast cancer
Steadman, J. A., & Hieken, T. J. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27797 · Cited by 2
Mahtani, R. L., Harpalani, N., Yan, F., Phiel, K. L., & Kovalenko, I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1419246 · Cited by 2
Gobbi, H., Carvalho, F. M., Brot, M. D., Waitzberg, Â. F. L., Silva, C. A. M., Soares, F. A., Landeiro, L. C. G., Rahal, R. M. S., & Barrios, C. H. (2024) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.20240313 · Cited by 2
“T-DXd consists of a compound in which a molecule of trastuzumab (an anti-HER2 antibody) binds to a molecule (linker) and incorporates a certain number of molecules from a potent cytotoxic agent (payload) 14-17 .”
BackgroundZhang, D., Taylor, A. B., Zhao, J. J., Endres, C. J., & Topletz‐Erickson, A. R. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01412-0 · Cited by 2
“In the HER2CLIMB phase II study (ONT-380-206, NCT02614794), tucatinib was evaluated in combination with trastuzumab and capecitabine (tucatinib combination group) or placebo in HER2+ mBC after progression on trastuzumab, per-tuzumab, and T-DM1 in any setting [7].”
Kaya, H., & Eroğlu, O. (2024) · Journal of Investigative Medicine · doi:10.1177/10815589241309603 · Cited by 2
Lossos, C., Sanchez, S., Nonogaki, H., Gabrielson, E. W., Cimino‐Mathews, A., & Maleki, Z. (2025) · Acta Cytologica · doi:10.1159/000546274 · Cited by 2
“While metastatic breast cancer remains a disease with no de fi nitive cure, there has been signi fi cant improvement in survival due to the introduction of targeted therapies [8, 9].”
CDK4/6 inhibition in HER2-positive breast cancer
Battisti, N. M. L., & Ring, A. E. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30164-9 · Cited by 3
Lüftner, D., Schneeweiß, A., Hartkopf, A. D., Müller, V., Wöckel, A., Janni, W., Ettl, J., Belleville, E., Schütz, F., Thill, M., et al. (2020) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1199-2881 · Cited by 2
“In San Antonio wurden die Ergebnisse der Studie HER2Climb mit 612 Patientinnen vorgestellt, die alle mit Trastuzumab/Pertuzumab sowie mit T‐DM1 vorbehandelt waren und im Median zuvor bereits 4 Therapielinien erhalten hatten [12].”
BackgroundSelf-citationde Matos, L. V., Fernandes, L., Louro, P., Plácido, A. N., Barros, M., & Vaz, F. (2021) · Current Oncology · doi:10.3390/curroncol28010050 · Cited by 2
Radiotherapy for Oligometastatic Non–Small Cell Lung Cancer: Past, Present, and Future
McCall, N. S., & Higgins, K. A. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3506.0311 · Cited by 2
COLOMATE challenge to overcome resistance in metastatic colorectal cancer
Yoshino, T. (2021) · ONCOLOGY · doi:10.46883/onc.2021.3510.0656 · Cited by 2
Breast Cancer Treatment in the Era of Precision Medicine
Vetter, M. H. F., & Kurzeder, C. (2020) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2020.05.020 · Cited by 2
Updated Austrian treatment algorithm in HER2+ metastatic breast cancer
Bartsch, R., Gampenrieder, S. P., Rinnerthaler, G., Petru, E., Egle, D., Petzer, A. L., Balić, M., Pluschnig, U., Sliwa, T., & Singer, C. F. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01987-9 · Cited by 2
“Thereafter, T-DXd or tucatinib [18, 20, 22, 48] may both be considered, although specific data on the use of third-generation agents in an old and/or comorbid population are still pending.”
BackgroundPrise en charge des métastases cérébrales en 2022
Schiappacasse, L., Kinj, R., Micheli, R. D., Mederos, N., Tuleasca, C., Cossu, G., Dunet, V., Levivier, M., Bourhis, J., & Hottinger, A. F. (2022) · JMIG · doi:10.53738/revmed.2022.18.782.976 · Cited by 2
De, S. K. (2022) · Wiley eBooks · doi:10.1002/9783527838561.ch6 · Cited by 2
Halima, A., Mayo, Z. S., Jung, E. W., Ellithi, M., Chao, S. T., Murphy, E. S., & Suh, J. H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822835-7.00045-7 · Cited by 2
Patel, K., Mukhi, H., Patel, A., Nathwani, N., Mehta, D., Sherak, J., Clinton, N., Pisarik, H., Brown, B., Rogers, S., et al. (2022) · The American Journal of Managed Care · doi:10.37765/ajmc.2022.88856 · Cited by 2
Austrian treatment algorithms in HER2-positive metastatic breast cancer: a 2022 update
Rinnerthaler, G., Singer, C. F., Petru, E., Egle, D., Petzer, A. L., Pluschnig, U., Gampenrieder, S. P., Pfeiler, G., Gnant, M., Grünberger, B., et al. (2022) · Wiener klinische Wochenschrift · doi:10.1007/s00508-022-02082-3 · Cited by 3
“tucatinib, trastuzumab and capecitabine can be considered the treatment of choice based on data from HER2CLIMB study [5, 13, 18, 19, 39].”
BackgroundPhase I study of LZM005 in patients with HER2-positive metastatic breast cancer
Xue, C., Li, H., Yao, H., Lin, Y., An, X., Chen, M., Huang, R., Li, L., Hu, A., Ni, M., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00501-2 · Cited by 2
Current Updates in Management of HER2-Positive and HER2-Low Breast Cancer
Thaper, A., Tran, J., & Ali, A. (2023) · Current Breast Cancer Reports · doi:10.1007/s12609-023-00486-2 · Cited by 2
Prognosis of breast cancer patients with brain metastasis treated with radiotherapy
Simonsen, M. K., Offersen, B. V., & Jensen, A. B. (2023) · Acta Oncologica · doi:10.1080/0284186x.2023.2238551 · Cited by 2
Putri, H. N., Firmansyah, M. T., Vanchapo, A. R., Lewar, E. S. B., & Tusi, J. S. (2023) · Journal of World Future Medicine Health and Nursing · doi:10.55849/health.v1i1.429 · Cited by 2
Targeted therapy for breast cancer
Frolova, M. A., & Стенина, М. Б. (2024) · Practical oncology · doi:10.31917/2503241 · Cited by 2
Bhatia, K. P., & Batra, A. (2025) · Springer eBooks · doi:10.1007/978-981-97-9847-6_15 · Cited by 2
Therapy for HER2-Positive Metastatic Breast Cancer
Dekker, T. J. A. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2004854 · Cited by 2
Comparative Effectiveness Research Needs to Consider Optimal Dosing and Scheduling
Seidman, A. D., de Stanchina, E., Norton, L., & Morikawa, A. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02355 · Cited by 2
Rizzo, A., Cusmai, A., Massafra, R., Bove, S., Comes, M. C., Fanizzi, A., Gadaleta‐Caldarola, G., Oreste, D., Zito, A., Giotta, F., et al. (2022) · Cancer Control · doi:10.1177/10732748221106267 · Cited by 2
“Stratification factors were the presence of brain metastases, Eastern Cooperative Oncology Group Performance Status (ECOG-PS) 0 or 1, and geographical region (US, Canada or rest of the world).(26,27) The HER2CLIMB study met all primary and secondary endpoints at the first interim analysis, and importantly, the seconda…”
BackgroundMethodMo, D., Luo, P., & Huang, J. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.1388 · Cited by 2
Kumar, S., Larson, R. A., Stecklein, S. R., Reddy, J. P., Debeb, B. G., Amos, R. A., Cologna, S. M., & Woodward, W. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.25.595905 · Cited by 2
Rivier, C., Méry, B., Rowinski, E., Sotton, S., Bouleftour, W., Bertoletti, L., Trédan, O., & Magné, N. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1983541 · Cited by 1
“described only two patients with cardiac failure, which is consistent with the results of the placebo-controlled trial [39].”
ResultFu, L., Liang, Y., Luo, M., Shen, J., Zhou, T., Liang, Y., Tang, X., Yuan, H., & Zeng, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1041111 · Cited by 1
Villacrés, J. M., Meza, Á. L., Ballén, D. F., Rodríguez, R. A. S., Ladino, A. S., Castillo, J. O. S., Mejía, F. C., Mosquera, C. L., Aristizábal, J. Á., Bruges, R. E., et al. (2023) · Revista Colombiana de Cancerología · doi:10.35509/01239015.868 · Cited by 1
Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments
Soltani, M., Sokoloff, L. J., & Fradley, M. G. (2023) · Current Oncology Reports · doi:10.1007/s11912-023-01427-z · Cited by 1
Dülgar, Ö., Türker, S., Başaran, G., Araz, M., Sümbül, A. T., Çağlayan, D., Gümüşay, Ö., Biter, S., Konca, A., Özen, M., et al. (2024) · Journal of Chemotherapy · doi:10.1080/1120009x.2024.2366683 · Cited by 1
“In the HER2CLIMB trial, among the brain metastatic patients pretreated with pertuzumab plus trastuzumab and TDM-1, in third-line, Tucatinib in combination with trastuzumab and capecitabine had better progression-free survival outcomes than in combination with placebo [16].”
Pabon, C. M., Yeboa, D. N., O'Brien, B. J., Majd, N., Wang, C., & Murphy, M. B. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-70 · Cited by 1
Kubeczko, M., Gabryś, D., Polakiewicz-Gilowska, A., Bobek‐Billewicz, B., & Jarząb, M. (2024) · Pharmaceuticals · doi:10.3390/ph17070927 · Cited by 1
“For the HER2-positive subtype and triple-negative breast cancer, recent approvals have expanded options with drugs such as tucatinib [67], trastuzumab deruxtecan [68], pembrolizumab [69], and sacituzumab govitecan [70].”
BackgroundStratagems for Breast Cancer Management in the Era of Nanotheranostics
Goel, H., Arora, P. K., Riya, Chawla, V., Singla, R., & Chawla, P. A. (2024) · Springer eBooks · doi:10.1007/978-981-97-3115-2_6 · Cited by 3
Hepatotoxicity of Anti-cancer Drugs
Bayram, D., & Uçar, G. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_344 · Cited by 2
Niraula, S., Gouli, S., Baran, A. M., O’Regan, R. M., Tyburski, H., Zhang, H., Hardy, S. J., Mohile, N. A., Anders, C. K., & Dhakal, A. (2024) · Clinical Breast Cancer · doi:10.1016/j.clbc.2024.09.019 · Cited by 1
Self-citationA Comprehensive Review of Advances in Molecular Diagnostics and Treatment of Trypanosomiasis
Abdulateef, S. M., & Abood, N. A. (2024) · INTERNATIONAL JOURNAL OF HEALTH & MEDICAL RESEARCH · doi:10.58806/ijhmr.2024.v3i10n02 · Cited by 1
Sumou, I. K., & Hui, C. V. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1470560 · Cited by 1
Drug Treatment Direction Based on the Molecular Mechanism of Breast Cancer Brain Metastasis
Zhang, Y., Shang, H., Zhang, J., Jiang, Y., Li, J., Xiong, H., & Chao, T. (2025) · Pharmaceuticals · doi:10.3390/ph18020262 · Cited by 2
Kou, F., Liu, H., Zhang, Y., Liao, X., Hu, L., Sun, J., Zhang, J., Xu, Y., Yao, L., & Xie, Y. (2025) · JCO Precision Oncology · doi:10.1200/po-24-00679 · Cited by 1
Anders, C. K., Neuberger, E. E., Bartley, K., Pittner, B. T., Sow, A., Wang, S., & Kaufman, P. A. (2025) · Cancer Control · doi:10.1177/10732748251327711 · Cited by 1
Self-citationTakeda, T., Matsumoto, J., Sakai, T., Iwata, N., Hamano, H., Koyama, T., Ariyoshi, N., & Zamami, Y. (2025) · British Journal of Clinical Pharmacology · doi:10.1002/bcp.70094 · Cited by 2
Valencia, G., Rioja, P., Peralta, O., Chirito, M., Mantilla, R., Castañeda, C. A., Morante, Z., Fuentes, H. A., Vidaurre, T., Calderón, M. J., et al. (2025) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234251342477 · Cited by 1
Yoshikawa, K. (2025) · Cureus · doi:10.7759/cureus.85011 · Cited by 1
Advancing treatment in HER2-positive metastatic breast cancer: the role of tucatinib
Fidler, D., Gelmon, K. A., & Simmons, C. E. (2025) · Future Oncology · doi:10.1080/14796694.2025.2529151 · Cited by 1
Self-citationThe ERBB Family of Receptor Tyrosine Kinases: Key Players in Cancer
Garcia, D. D., Marrocco, I., Romaniello, D., & Uribe, M. L. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_2 · Cited by 1
Wang, C.-Y., Lin, C., Yang, H., Liu, C., Lai, J., Wu, H.-M., Chung, W., Shiau, C.-Y., Guo, W.-Y., & Lee, C. (2025) · Journal of Neuro-Oncology · doi:10.1007/s11060-025-05188-6 · Cited by 1
“In our cohort, patients with HER2-positive and hormone receptor–positive tumors exhibited significantly improved survival outcomes, likely due to the effectiveness of sys - temic HER2-targeted agents, which were administered to all HERz2-positive patients [9, 20, 36, 37 ].”
Current Understanding of Neuroendocrine Tumors of Breast - An Integrated Review
Singhal, B. M., & Kewlani, V. (2025) · International Journal of Recent Surgical and Medical Sciences · doi:10.25259/ijrsms_40_2025 · Cited by 1
Huisman, R. G., van Schie, P., Merckel, L. G., Wiersma, T., Knegjens, J., Jansen, E. P. M., Compter, A., Brandsma, D., Bot, M., Hoogmoed, J., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.111127 · Cited by 1
Arenhardt, M. P., Vieira, C. M., & Nogueira‐Rodrigues, A. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.100997 · Cited by 1
Chávez‐MacGregor, M., Gligorov, J., Mouta, J., Meerveld, M. V., Wolkensdorfer, Z., Attfield, G., Lewis, A., & Cardoso, F. (2025) · The Breast · doi:10.1016/j.breast.2025.104607 · Cited by 1
“For people with brain metastases, the tyrosine kinase inhibitor tucatinib also provided OS benefit, as seen in the HER2CLIMB-01 trial [60,61].”
Basmadjian, R. B., Cheung, W. Y., Boyne, D. J., Henning, J., Moldaver, D., Shokar, S., Carbonell, C., & Brenner, D. R. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101021 · Cited by 1
A review of current and emerging therapies in breast cancer: implications for older adults
Schreiber, A., Verduzco-Aguirre, H. C., Giangiuli, S., Aranda-Gutierrez, A., Roy, S., & Soto‐Pérez‐de‐Celis, E. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2580349 · Cited by 1
“…the HER2CLIMB trial, which demonstrated that the addition of the tyrosine kinase inhibitor (TKI) tucatinib significantly improved PFS (7.8 vs. 5.6 months; HRa 0.54; 95% CI, 0.42–0.71) and OS (24.7 vs. 19.2 months; HRa 0.73; 95% CI, 0.59–0.90) compared to trastuzumab and capecitabine alone [46,47].”
InfluentialKrasnow, N. A., Jayaraj, M., Salans, M. A., Kuwahara, K., Zhou, M. H., Fisch, S. C., Boreta, L. C., Braunstein, S. E., Aghi, M. K., Batra-Sharma, H., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02121-7 · Cited by 3
“These lipophilic small molecules are thought to readily penetrate the blood brain barrier, with studies demonstrating improved survival outcomes in patients with MBC BMs that are treated with these therapies [13–15].”
Rombach, A., Geissler, M., Liu, X., Qasem, L., Stange, L., Prinz, V., Jussen, D., Landolsi, S., Kokkaliaris, K. D., Medyouf, H., et al. (2025) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2025.102055 · Cited by 1
Schiele, A., Bernhardt, D., Welzel, T., Thalmann, P., König, L., Eichkorn, T., Krämer, A., Lang, K., Lentz-Hommertgen, A., Weykamp, F., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.111279 · Cited by 1
Sano, H., Hayashi, H., Nakao, N., Hosoi, H., & Kondo, S. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2591813 · Cited by 1
“Other frequently encountered toxicities of HER2-targeted therapies include fatigue, nausea, hematological toxicities, hepatotoxicity, and peripheral neuropathy [13,59,62].”
InfluentialAntibody-Based Therapeutics in Breast Cancer: Clinical and Translational Perspectives
Balata, A., & Pogoda, K. (2025) · Antibodies · doi:10.3390/antib15010003 · Cited by 2
“Tucatinib plus trastuzumab and capecitabine improved mPFS to 7.8 vs. 5.6 months in the control arm (HR 0.54; p < 0.001) and prolonged OS, including in patients with brain metastases [22].”
InfluentialEfficacy of dual HER2 blockade in neoadjuvant HER2-positive breast cancer: a meta-analysis of RCTs
Chen, W. K., Yang, L., Zhang, J., & Yuan, Y. (2026) · Systematic Reviews · doi:10.1186/s13643-025-03058-w · Cited by 1
Ko, H., Choi, S.-Y., Kim, D., & Lee, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1778267 · Cited by 1
Zare, A., Khaboushan, A. S., Mohammadzadeh, I., Mortezaei, A., Zare, A., Hajikarimloo, B., Ghalehtaki, R., Park, D. J., & Chang, S. D. (2026) · Neurosurgical Review · doi:10.1007/s10143-025-04097-6 · Cited by 1
“Significant OS and intra - cranial PFS benefits have been demonstrated with a tuca - tinib-based treatment, even in patients with active brain metastases [51, 52].”
Benchmarking the Ligand–HER2 Interactions Using Machine Learning and Molecular Dynamics Simulations
Truong, D. T., Dao, Q. T., Tran, T. T. M., Nguyen, N. H., Nguyen-Thao, M.-K., Nam, N., Dung, D. T. M., & Nguyen, M. T. (2026) · ACS Omega · doi:10.1021/acsomega.5c10459 · Cited by 1
Steele, E. M., Hall, J. T., Lui, K., Darawsheh, R., Shumway, J., Carey, L. A., Reeder-Hayes, K. E., Lee, C. B., Moschos, S. J., Collichio, F. A., et al. (2026) · Journal of Neuro-Oncology · doi:10.1007/s11060-026-05450-5 · Cited by 1
“Prior studies exist that report rates of radiation necrosis for individual targeted agents, but heterogeneous populations and treatment parameters complicate comparisons of rates between classes of agents, of an intact BBB [24 –26].”
Self-citationBreast cancer brain metastasis: from molecular insights to therapeutic innovation
Han, X., Ma, W., & Zhao, W. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1801614 · Cited by 3
“This randomized phase III study prospectively enrolled patients with both stable and active brain metastases and demonstrated that the addition of tucatinib to trastuzumab and capecitabine signi fi cantly improved CNS progression-free survival and OS in patients with baseline brain metastases (163).”
Pero, S. C., Shukla, G. S., Sun, Y., Barrantes-Reynolds, R., Hartman, C. J., Ackerman, M. E., Mei, L., Zhang, F., Fournier, M. R., & Krag, D. N. (2026) · Scientific Reports · doi:10.1038/s41598-026-46751-z · Cited by 1
“In addition, 0.2 mg of rat anti-mouse PD-1 was intraperitoneally injected into these mice on days 3, 5, 7, 9, and 11 after tumor implantation (Fig.”
InfluentialLong-term cardiotoxicity outcomes of trastuzumab and cardiac safety of novel HER2-targeted therapies
Esen, S. A., Uncu, D., & Sendur, M. A. N. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2667402 · Cited by 1
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103715 · Cited by 1
“These agents have demonstrated superior efficacy compared with earlier standards, although differences in toxicity profiles, particularly interstitial lung disease with trastuzumab deruxtecan, necessitate careful monitoring [113–116].”
Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury
Chen, L., Li, G.-H., & Li, C.-Y. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2674136 · Cited by 1
Majewska, A., Byrski, T., & Falco, M. (2026) · Cancers · doi:10.3390/cancers18101659 · Cited by 1
“Despite therapeutic advances, the blood–brain barrier limits the efficacy of many drugs, and prognosis is determined primarily by clinical factors, including the number of BM, control of extracranial disease, and the availability of local and systemic treatment options [12].”
Recent advances in HER2-targeted inhibitors for cancer therapy
Zhu, W., & Lu, X. (2026) · Pharmaceutical Science Advances · doi:10.1016/j.pscia.2026.100127 · Cited by 2
“5.4 months) [51].”
InfluentialVilla, M., Malighetti, F., Villa, A. M., Cordani, N., Aroldi, A., Zambon, A., Ramazzotti, D., & Mologni, L. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08420-7 · Cited by 1
“Given its established clinical approval [47, 48], tucatinib was prioritized as a partner of palbociclib in subsequent analyses.”
Modi, S., Murthy, R. K., Chien, A. J., Lin, N., McAndrew, N. P., Specht, J. M., Zelnak, A. B., Ramos, J., Xie, D., Ho, J., et al. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.05.010 · Cited by 5
Self-citationWang, Y., Zhang, M., Zhang, X., Guo, T., Wang, Y., & YU, C. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105497 · Cited by 1
Metadata
- Authors
- Murthy, R. K., Loi, S., Okines, A., Paplomata, E., Hamilton, E., Hurvitz, S. A., Lin, N. U., Borges, V., Abramson, V., Anders, C., Bedard, P. L., Oliveira, M., Jakobsen, E., Bachelot, T., Shachar, S. S., Müller, V., Braga, S., Duhoux, F. P., Greil, R., Cameron, D., Carey, L. A., Curigliano, G., Gelmon, K., Hortobagyi, G., Krop, I., Loibl, S., Pegram, M., Slamon, D., Palanca-Wessels, M. C., Walker, L., Feng, W., & Winer, E. P.
- Affiliations
- Royal Marsden NHS Foundation Trust (GB)
- From M.D. Anderson Cancer Center, Houston (R.K.M., G.H.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (S. Loi); the Royal Marsden NHS Foundation Trust, London (A.O.), and Edinburgh Cancer Research Centre, Edinburgh (D.C.) — both in the United Kingdom; Winship Cancer Institute, Atlanta (E.P.); Sarah Cannon Research Institute/Tennessee Oncology–Nashville (E.H.) and Vanderbilt University Medical Center (V.A.), Nashville; University of California, Los Angeles, Medical Center–Jonsson...
- BC Cancer Agency (CA)
- ORCID
- Murthy, Rashmi K.
- Loi, Sherene
- Okines, Alicia
- Hamilton, Erika
- Hurvitz, Sara A.
- Borges, Virginia
- Abramson, Vandana
- Anders, Carey
- Bedard, Philippe L.
- Oliveira, Mafalda
- Jakobsen, Erik
- Bachelot, Thomas
- Shachar, Shlomit S.
- Müller, Volkmar
- Braga, Sofia
- Duhoux, Francois P.
- Greil, Richard
- Cameron, David
- Curigliano, Giuseppe
- Gelmon, Karen
- Krop, Ian
- Loibl, Sibylle
- Pegram, Mark
- Slamon, Dennis
- Palanca-Wessels, M. Corinna
- Feng, Wentao
- Winer, Eric P.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-02-13
- Volume
- 382
- Issue
- 7
- Pages
- 597-609
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2995808512
- Cited by
- 1,326
- References
- 29
- Citations by year
- 2026: 118 · 2025: 158 · 2024: 203 · 2023: 197 · 2022: 252 · 2021: 244 · 2020: 152
- FWCI
- 67.71
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- HAL (submittedVersion)
- Digital Access to Libraries (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion, other-oa)
- UNC Libraries
- Funders
- Seattle Genetics
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- tucatinib, HER2-positive metastatic breast cancer, trastuzumab, capecitabine, HER2 tyrosine kinase inhibitor, brain metastases, progression-free survival, overall survival, pertuzumab, trastuzumab emtansine, HER2-targeted therapy, diarrhea, hand-foot syndrome
- MeSH terms
- Trastuzumab, Capecitabine, Progression-Free Survival, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Diarrhea, Double-Blind Method, Female, Humans, Middle Aged, Oxazoles, Protein-Tyrosine Kinases, Pyridines, Quinazolines, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate, Consolidation Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.